🇺🇸 FDA
Pipeline program

Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

FLECA-ED

Phase 3 small_molecule active

Quick answer

Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση for Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35% is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials